Cargando…

Vascular miR-181b controls tissue factor-dependent thrombogenicity and inflammation in type 2 diabetes

BACKGROUND: Diabetes mellitus is characterized by chronic vascular inflammation leading to pathological expression of the thrombogenic full length (fl) tissue factor (TF) and its isoform alternatively-spliced (as) TF. Blood-borne TF promotes factor (F) Xa generation resulting in a pro-thrombotic sta...

Descripción completa

Detalles Bibliográficos
Autores principales: Witkowski, Marco, Witkowski, Mario, Saffarzadeh, Mona, Friebel, Julian, Tabaraie, Termeh, Ta Bao, Loc, Chakraborty, Aritra, Dörner, Andrea, Stratmann, Bernd, Tschoepe, Diethelm, Winter, Samantha J., Krueger, Andreas, Ruf, Wolfram, Landmesser, Ulf, Rauch, Ursula
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7027062/
https://www.ncbi.nlm.nih.gov/pubmed/32066445
http://dx.doi.org/10.1186/s12933-020-0993-z
_version_ 1783498791250296832
author Witkowski, Marco
Witkowski, Mario
Saffarzadeh, Mona
Friebel, Julian
Tabaraie, Termeh
Ta Bao, Loc
Chakraborty, Aritra
Dörner, Andrea
Stratmann, Bernd
Tschoepe, Diethelm
Winter, Samantha J.
Krueger, Andreas
Ruf, Wolfram
Landmesser, Ulf
Rauch, Ursula
author_facet Witkowski, Marco
Witkowski, Mario
Saffarzadeh, Mona
Friebel, Julian
Tabaraie, Termeh
Ta Bao, Loc
Chakraborty, Aritra
Dörner, Andrea
Stratmann, Bernd
Tschoepe, Diethelm
Winter, Samantha J.
Krueger, Andreas
Ruf, Wolfram
Landmesser, Ulf
Rauch, Ursula
author_sort Witkowski, Marco
collection PubMed
description BACKGROUND: Diabetes mellitus is characterized by chronic vascular inflammation leading to pathological expression of the thrombogenic full length (fl) tissue factor (TF) and its isoform alternatively-spliced (as) TF. Blood-borne TF promotes factor (F) Xa generation resulting in a pro-thrombotic state and cardiovascular complications. MicroRNA (miR)s impact gene expression on the post-transcriptional level and contribute to vascular homeostasis. Their distinct role in the control of the diabetes-related procoagulant state remains poorly understood. METHODS: In a cohort of patients with poorly controlled type 2 diabetes (n = 46) plasma levels of miR-181b were correlated with TF pathway activity and markers for vascular inflammation. In vitro, human microvascular endothelial cells (HMEC)-1 and human monocytes (THP-1) were transfected with miR-181b or anti-miR-181b and exposed to tumor necrosis factor (TNF) α or lipopolysaccharides (LPS). Expression of TF isoforms, vascular adhesion molecule (VCAM) 1 and nuclear factor (NF) κB nuclear translocation was assessed. Moreover, aortas, spleen, plasma, and bone marrow-derived macrophage (BMDM)s of mice carrying a deletion of the first miR-181b locus were analyzed with respect to TF expression and activity. RESULTS: In patients with type 2 diabetes, plasma miR-181b negatively correlated with the procoagulant state as evidenced by TF protein, TF activity, d-dimer levels as well as markers for vascular inflammation. In HMEC-1, miR-181b abrogated TNFα-induced expression of flTF, asTF, and VCAM1. These results were validated using the anti-miR-181b. Mechanistically, we confirmed a miR-181b-mediated inhibition of importin-α3 (KPNA4) leading to reduced nuclear translocation of the TF transcription factor NFκB. In THP-1, miR-181b reduced both TF isoforms and FXa generation in response to LPS due to targeting phosphatase and tensin homolog (PTEN), a principal inducer for TF in monocytes. Moreover, in miR-181−/− animals, we found that reduced levels of miR-181b were accompanied by increased TF, VCAM1, and KPNA4 expression in aortic tissue as well as increased TF and PTEN expression in spleen. Finally, BMDMs of miR-181−/− mice showed increased TF expression and FXa generation upon stimulation with LPS. CONCLUSIONS: miR-181b epigenetically controls the procoagulant state in diabetes. Reduced miR-181b levels contribute to increased thrombogenicity and may help to identify individuals at particular risk for thrombosis.
format Online
Article
Text
id pubmed-7027062
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-70270622020-02-24 Vascular miR-181b controls tissue factor-dependent thrombogenicity and inflammation in type 2 diabetes Witkowski, Marco Witkowski, Mario Saffarzadeh, Mona Friebel, Julian Tabaraie, Termeh Ta Bao, Loc Chakraborty, Aritra Dörner, Andrea Stratmann, Bernd Tschoepe, Diethelm Winter, Samantha J. Krueger, Andreas Ruf, Wolfram Landmesser, Ulf Rauch, Ursula Cardiovasc Diabetol Original Investigation BACKGROUND: Diabetes mellitus is characterized by chronic vascular inflammation leading to pathological expression of the thrombogenic full length (fl) tissue factor (TF) and its isoform alternatively-spliced (as) TF. Blood-borne TF promotes factor (F) Xa generation resulting in a pro-thrombotic state and cardiovascular complications. MicroRNA (miR)s impact gene expression on the post-transcriptional level and contribute to vascular homeostasis. Their distinct role in the control of the diabetes-related procoagulant state remains poorly understood. METHODS: In a cohort of patients with poorly controlled type 2 diabetes (n = 46) plasma levels of miR-181b were correlated with TF pathway activity and markers for vascular inflammation. In vitro, human microvascular endothelial cells (HMEC)-1 and human monocytes (THP-1) were transfected with miR-181b or anti-miR-181b and exposed to tumor necrosis factor (TNF) α or lipopolysaccharides (LPS). Expression of TF isoforms, vascular adhesion molecule (VCAM) 1 and nuclear factor (NF) κB nuclear translocation was assessed. Moreover, aortas, spleen, plasma, and bone marrow-derived macrophage (BMDM)s of mice carrying a deletion of the first miR-181b locus were analyzed with respect to TF expression and activity. RESULTS: In patients with type 2 diabetes, plasma miR-181b negatively correlated with the procoagulant state as evidenced by TF protein, TF activity, d-dimer levels as well as markers for vascular inflammation. In HMEC-1, miR-181b abrogated TNFα-induced expression of flTF, asTF, and VCAM1. These results were validated using the anti-miR-181b. Mechanistically, we confirmed a miR-181b-mediated inhibition of importin-α3 (KPNA4) leading to reduced nuclear translocation of the TF transcription factor NFκB. In THP-1, miR-181b reduced both TF isoforms and FXa generation in response to LPS due to targeting phosphatase and tensin homolog (PTEN), a principal inducer for TF in monocytes. Moreover, in miR-181−/− animals, we found that reduced levels of miR-181b were accompanied by increased TF, VCAM1, and KPNA4 expression in aortic tissue as well as increased TF and PTEN expression in spleen. Finally, BMDMs of miR-181−/− mice showed increased TF expression and FXa generation upon stimulation with LPS. CONCLUSIONS: miR-181b epigenetically controls the procoagulant state in diabetes. Reduced miR-181b levels contribute to increased thrombogenicity and may help to identify individuals at particular risk for thrombosis. BioMed Central 2020-02-17 /pmc/articles/PMC7027062/ /pubmed/32066445 http://dx.doi.org/10.1186/s12933-020-0993-z Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Original Investigation
Witkowski, Marco
Witkowski, Mario
Saffarzadeh, Mona
Friebel, Julian
Tabaraie, Termeh
Ta Bao, Loc
Chakraborty, Aritra
Dörner, Andrea
Stratmann, Bernd
Tschoepe, Diethelm
Winter, Samantha J.
Krueger, Andreas
Ruf, Wolfram
Landmesser, Ulf
Rauch, Ursula
Vascular miR-181b controls tissue factor-dependent thrombogenicity and inflammation in type 2 diabetes
title Vascular miR-181b controls tissue factor-dependent thrombogenicity and inflammation in type 2 diabetes
title_full Vascular miR-181b controls tissue factor-dependent thrombogenicity and inflammation in type 2 diabetes
title_fullStr Vascular miR-181b controls tissue factor-dependent thrombogenicity and inflammation in type 2 diabetes
title_full_unstemmed Vascular miR-181b controls tissue factor-dependent thrombogenicity and inflammation in type 2 diabetes
title_short Vascular miR-181b controls tissue factor-dependent thrombogenicity and inflammation in type 2 diabetes
title_sort vascular mir-181b controls tissue factor-dependent thrombogenicity and inflammation in type 2 diabetes
topic Original Investigation
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7027062/
https://www.ncbi.nlm.nih.gov/pubmed/32066445
http://dx.doi.org/10.1186/s12933-020-0993-z
work_keys_str_mv AT witkowskimarco vascularmir181bcontrolstissuefactordependentthrombogenicityandinflammationintype2diabetes
AT witkowskimario vascularmir181bcontrolstissuefactordependentthrombogenicityandinflammationintype2diabetes
AT saffarzadehmona vascularmir181bcontrolstissuefactordependentthrombogenicityandinflammationintype2diabetes
AT friebeljulian vascularmir181bcontrolstissuefactordependentthrombogenicityandinflammationintype2diabetes
AT tabaraietermeh vascularmir181bcontrolstissuefactordependentthrombogenicityandinflammationintype2diabetes
AT tabaoloc vascularmir181bcontrolstissuefactordependentthrombogenicityandinflammationintype2diabetes
AT chakrabortyaritra vascularmir181bcontrolstissuefactordependentthrombogenicityandinflammationintype2diabetes
AT dornerandrea vascularmir181bcontrolstissuefactordependentthrombogenicityandinflammationintype2diabetes
AT stratmannbernd vascularmir181bcontrolstissuefactordependentthrombogenicityandinflammationintype2diabetes
AT tschoepediethelm vascularmir181bcontrolstissuefactordependentthrombogenicityandinflammationintype2diabetes
AT wintersamanthaj vascularmir181bcontrolstissuefactordependentthrombogenicityandinflammationintype2diabetes
AT kruegerandreas vascularmir181bcontrolstissuefactordependentthrombogenicityandinflammationintype2diabetes
AT rufwolfram vascularmir181bcontrolstissuefactordependentthrombogenicityandinflammationintype2diabetes
AT landmesserulf vascularmir181bcontrolstissuefactordependentthrombogenicityandinflammationintype2diabetes
AT rauchursula vascularmir181bcontrolstissuefactordependentthrombogenicityandinflammationintype2diabetes